Related references
Note: Only part of the references are listed.Glycosylation of therapeutic proteins in different production systems
Rolf G. Werner et al.
ACTA PAEDIATRICA (2007)
Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers
Minghong Jiang et al.
CLINICAL CANCER RESEARCH (2006)
Challenges in therapeutic glycoprotein production
Natarajan Sethuraman et al.
CURRENT OPINION IN BIOTECHNOLOGY (2006)
Basic concepts in Q membrane chromatography for large-scale antibody production
JX Zhou et al.
BIOTECHNOLOGY PROGRESS (2006)
Antibody targeted drugs as cancer therapeutics
D Schrama et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Optimisation of the cellular metabolism of glycosylation for recombinant proteins produced by mammalian cell systems
M. Butler
CYTOTECHNOLOGY (2006)
Elimination mechanisms of therapeutic monoclonal antibodies
MA Tabrizi et al.
DRUG DISCOVERY TODAY (2006)
Characterization of adeno-associated virus genomes isolated from human tissues
BC Schnepp et al.
JOURNAL OF VIROLOGY (2005)
Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies
A Iannello et al.
CANCER AND METASTASIS REVIEWS (2005)
Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies
D Geng et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2005)
Intrabodies as drug discovery tools and therapeutics
M Stocks
CURRENT OPINION IN CHEMICAL BIOLOGY (2005)
Regulatable gene expression systems for gene therapy applications: Progress and future challenges
S Goverdhana et al.
MOLECULAR THERAPY (2005)
In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies
A Lamikanra et al.
GENE THERAPY (2005)
Stable antibody expression at therapeutic levels using the 2A peptide
JM Fang et al.
NATURE BIOTECHNOLOGY (2005)
Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial
M Schmidt et al.
BLOOD (2005)
Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins
D Ternant et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2005)
Monoclonal antibody successes in the clinic
JM Reichert et al.
NATURE BIOTECHNOLOGY (2005)
Monoclonal antibody therapy of cancer
GP Adams et al.
NATURE BIOTECHNOLOGY (2005)
Monoclonal antibodies produced by muscle after plasmid injection and electroporation
TE Tjelle et al.
MOLECULAR THERAPY (2004)
Antibodies and gene therapy: teaching old 'magic bullets' new tricks
L Sanz et al.
TRENDS IN IMMUNOLOGY (2004)
Economic aspects of commercial manufacture of biopharmaceuticals
RG Werner
JOURNAL OF BIOTECHNOLOGY (2004)
Pharmacokinetic aspects of biotechnology products
L Tang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Structure-immunogenicity relationships of therapeutic proteins
S Hermeling et al.
PHARMACEUTICAL RESEARCH (2004)
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1
S Hacein-Bey-Abina et al.
SCIENCE (2003)
Cell microencapsulation technology for biomedical purposes:: novel insights and challenges
G Orive et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2003)
Immunotherapy: past, present and future
TA Waldmann
NATURE MEDICINE (2003)
Genetic fate of recombinant adeno-associated virus vector genomes in muscle
BC Schnepp et al.
JOURNAL OF VIROLOGY (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Stevens-Johnson syndrome after treatment with rituximab
S Lowndes et al.
ANNALS OF ONCOLOGY (2002)
Encapsulated cell technology:: from research to market
G Orive et al.
TRENDS IN BIOTECHNOLOGY (2002)
High in vivo production of a model monoclonal antibody on adenoviral gene transfer
D Noël et al.
HUMAN GENE THERAPY (2002)
Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv
WO Arafat et al.
GENE THERAPY (2002)
Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers
RS Herbst et al.
SEMINARS IN ONCOLOGY (2002)
A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1
C Armbruster et al.
AIDS (2002)
Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
F Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment
TA Davis et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies
M Pelegrin et al.
HUMAN GENE THERAPY (2000)
Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides
A Knappik et al.
JOURNAL OF MOLECULAR BIOLOGY (2000)
Share Paper
